FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy

More than 1.6 Million Children and Teens in the U.S. are Allergic to Peanuts

FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy Palforzia_Logo_RGB_Large_v02

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA

[Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and older. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. PALFORZIA is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

https://www.businesswire.com/news/home/20200131005593/en/FDA-Approves-Aimmune%E2%80%99s-PALFORZIA%E2%84%A2-Treatment-Peanut-Allergy

FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy

FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy

Anarcho-Capitalist Categorical Imperatives

AnCaps In Science, Technology & Environment